Related by context. All words. (Click for frequent words.) 61 guideline concordant 59 oral prednisolone 58 cefepime 57 poststroke depression 57 medication nonadherence 57 Lofexidine 57 psychiatric comorbidity 56 nonadherence 56 divalproex sodium 56 neuropsychiatric symptoms 56 psychiatric morbidity 56 erection hardness 55 atypical antipsychotic medications 55 acamprosate calcium 55 antioxidant supplementation 55 comorbid psychiatric 55 albumin excretion 55 BPS IC 55 pharmacological therapy 55 psychiatric comorbidities 55 affective psychoses 55 serum PTH 54 serum cotinine 54 daytime somnolence 54 CPAP adherence 54 rhGH 54 interpersonal psychotherapy 54 opiate dependence 54 oral anticoagulant therapy 54 somatic symptoms 54 functional gastrointestinal disorders 54 atherothrombotic 54 neuroleptic 54 BPH LUTS 54 IntroductionThe 53 cortisol secretion 53 Suicidal ideation 53 generalisability 53 albumin excretion rate 53 cardiac autonomic 53 salmeterol fluticasone 53 sub syndromal 53 antidepressant efficacy 53 urodynamic parameters 53 oncological outcomes 53 dosing frequency 53 antipsychotic prescribing 53 somatoform disorders 53 comorbid depression 53 hepatic encephalopathy HE 53 SSRI SNRI 53 Dextofisopam 53 neuropsychological impairments 53 oxcarbazepine 52 somatostatin analogs 52 agomelatine 52 NIHSS score 52 antiarrhythmic drug 52 certolizumab 52 dosage regimens 52 TNF antagonist 52 atherothrombotic disease 52 concomitant AEDs 52 INVEGA SUSTENNA 52 oral anticoagulation 52 olanzapine LAI 52 corticosteroid dose 52 rufinamide 52 CRF antagonists 52 tacrolimus ointment 52 acute mania 52 HbA 1C 52 Psychosocial interventions 52 renoprotective 52 riociguat 52 Abilify aripiprazole 52 plasma cortisol 52 MoxDuo TM IR 52 AChE inhibitors 52 convergent validity 52 thyrotropin 52 CTEPH 52 timepoints 52 p = #.# [003] 52 symptom severity 52 pharmacological therapies 52 depressive symptomatology 52 meta analytic 52 alteplase 52 MYLOTARG 52 XEPLION R 51 symptomatology 51 comorbid disorders 51 anticholinergic agents 51 alexithymia 51 INVEGA ® SUSTENNA TM 51 phenelzine 51 nasal polyposis 51 thromboprophylaxis 51 octreotide LAR 51 bioprosthetic valve 51 Symptom severity 51 hypochondriasis 51 premorbid 51 CORE OM 51 vasopressor 51 viral kinetics 51 primary aldosteronism 51 UPDRS scores 51 subscale scores 51 serum urate 51 Adverse effects 51 titrated glipizide 51 VTE prophylaxis 51 psychometric properties 51 lipid lowering agents 51 antitumor effect 51 venlafaxine XR 51 nortriptyline 51 HRQL 51 antiepileptics 51 pharmacological interventions 51 Zevalin consolidation 51 sensory gating 51 antiandrogen 51 neuroleptics 51 methotrexate monotherapy 51 OPRM1 51 attain statistical significance 51 hematologic parameters 51 myocardial dysfunction 51 dyspnoea 51 solifenacin 51 hyperalgesia 51 neuropsychological assessment 51 unmeasured confounding 51 pharmacodynamic parameters 51 LUTS 51 CLBP 51 Interpersonal psychotherapy 51 OSAHS 51 hepatic insufficiency 51 aripiprazole 51 clomipramine 51 TNF alpha inhibitor 51 antiangiogenic therapy 51 selenium supplementation 51 fibromyalgia syndrome 51 venous thromboembolic disease 50 reboxetine 50 interpersonal psychotherapy IPT 50 chronicity 50 vernakalant hydrochloride 50 5 HTTLPR genotype 50 OAB symptoms 50 systemic hypotension 50 posttreatment 50 non pharmacological interventions 50 gene rearrangement 50 HbA1C levels 50 Topical corticosteroids 50 citalopram 50 PNH patients 50 comorbid anxiety 50 CIMZIA ™ 50 aldosterone antagonist 50 anagrelide 50 divalproex 50 MS DRG 50 pharmacological treatments 50 INRs 50 symptomatic intracranial hemorrhage 50 efalizumab 50 acute subacute 50 predictive validity 50 glucose homeostasis 50 inotropic 50 DAS# remission 50 MBCT 50 paliperidone palmitate 50 COPD exacerbations 50 MMSE scores 50 intravascular volume 50 neurosensory 50 β blockers 50 autonomic dysfunction 50 poststroke 50 GnRH agonists 50 rotigotine 50 fluvoxamine 50 sacral neuromodulation 50 nonpsychiatric 50 pharmacotherapies 50 reperfusion therapy 50 Likert scale 50 Y BOCS 50 neurocognitive deficits 50 perfusion abnormalities 50 HAQ DI 50 antidepressant monotherapy 50 serum lipid 50 empiric treatment 50 tapentadol ER 50 glomerular filtration 50 immunosuppressives 50 inflammatory biomarkers 50 poor metabolizers 50 INVEGA ® 50 chronic LBP 50 thrombolytic agents 50 maximal doses 50 IVTA 50 Subgroup analyzes 50 inotropes 50 rituximab monotherapy 50 extracellular dopamine 50 adrenal suppression 50 psychopharmacologic 50 chronic thromboembolic pulmonary 50 antidepressant therapy 50 renal cysts 50 chemosensitivity 50 KDOQI 50 HbF 50 darunavir r 50 analgesic efficacy 50 PMBs 50 SSRI citalopram 50 differential gene expression 50 levodopa induced dyskinesia 50 elevated ALT 50 psychosocial variables 50 thromboembolic disease 50 neuro psychiatric disorders 50 electrophysiologic 50 demonstrated clinically meaningful 50 HPA axis 49 desvenlafaxine 49 tiagabine 49 intranasal corticosteroids 49 analgesic medications 49 DSM IV diagnosis 49 transdermal testosterone 49 Calcium intake 49 serum lipid levels 49 syndromic 49 euthymic 49 antidepressive 49 untreated psychosis 49 psychosocial functioning 49 neurodevelopmental outcome 49 logistic regression models 49 antiplatelet medications 49 Circadin 49 Valdoxan 49 depressive disorders 49 thyrotropin levels 49 microbiologically evaluable 49 serum bicarbonate 49 RSD# oral 49 subcutaneous methylnaltrexone 49 PKC inhibitors 49 serum sodium levels 49 comorbid illnesses 49 bezafibrate 49 LMN cream 49 macrovascular disease 49 DMARD 49 plasma pharmacokinetics 49 ziconotide 49 NIH CPSI 49 Helicobacter pylori eradication 49 GH deficiency 49 epoetin alpha 49 MAGE A3 ASCI 49 oncologic outcomes 49 tolterodine ER 49 adverse cytogenetics 49 antiepileptic medications 49 underdiagnosis 49 GnRH agonist 49 thrombotic complications 49 sociodemographic variables 49 neurocognitive functioning 49 neuroleptic drugs 49 hypoglycemic events 49 anticholinergic medication 49 thorough QT 49 CHD mortality 49 LHRH agonists 49 Cognitive behavioral 49 CD# upregulation 49 DPNP 49 serotonin reuptake inhibitors 49 stavudine d4T 49 PbR 49 tipranavir 49 familial clustering 49 EFFEXOR XR 49 femoral neck fracture 49 AMHP 49 scintigraphic 49 angiotensin converting enzyme inhibitor 49 corticosteroid therapy 49 empirically validated 49 urodynamic 49 myeloproliferative diseases 49 systemic corticosteroid 49 INTEGRILIN 49 glycosylated hemoglobin levels 49 eszopiclone 49 NNT = 49 Uprima 49 oral corticosteroid 49 donepezil 49 malignant neoplasms 49 inhaled glucocorticoids 49 pharmacotherapeutic 49 HIV HCV coinfected 49 depressive symptom 49 hyperuricaemia 49 postinjury 49 comorbid conditions 49 intraobserver 49 selegiline 49 pharmacologic treatments 49 mania hypomania 49 psychophysiological 49 ß blockers 49 Primary endpoints 49 interrater reliability 49 Cipralex ® 49 somatization disorder 49 neurocognitive function 49 androgen suppression 49 LTBI 49 HbA 1c 49 carotid IMT 49 cranial irradiation 49 ACCORD Lipid 49 Major Depressive Disorder MDD 49 urinary albumin excretion 49 diagnosable mental disorders 49 quetiapine 49 depressive symptoms 49 postdischarge 49 plasminogen activators 49 HAART initiation 49 intracranial hemorrhage ICH 49 antimuscarinic 49 CDI recurrence 49 thienopyridine 49 acute myocardial infarction MI 49 venlafaxine Effexor 49 postoperative mortality 49 oral antidiabetes 49 ejection fractions 49 ICSs 49 androgen deprivation 49 periprocedural MI 49 antimicrobial prophylaxis 49 antihypertensive medication 49 inspiratory flow 49 Heritability 49 MDCT scans 49 platelet reactivity 49 EORTC QLQ C# 49 MIRAPEX 49 flutamide 49 lacosamide 49 affective disorders 48 shorter telomere length 48 comorbid substance 48 myopathy rhabdomyolysis 48 constipation OIC 48 GLP 1R 48 KAPIDEX 48 pulse amplitude 48 MGd 48 neurobehavioural 48 IOP lowering 48 urate lowering therapy 48 sertraline 48 anxiolytic 48 cerebral perfusion 48 sotalol 48 AGGRASTAT ® tirofiban hydrochloride 48 EDSS scores 48 GLP1 agonist 48 antidiabetic medications 48 Afatinib 48 telerehabilitation 48 canakinumab 48 carbidopa levodopa 48 epoprostenol 48 neuropsychiatric diseases 48 pegylated interferon ribavirin 48 CCyR 48 adalimumab 48 FOSRENOL ® 48 L PPDS 48 interferon ribavirin 48 haematologic 48 antiandrogens 48 moderately emetogenic 48 polyarticular 48 Mycophenolate mofetil 48 sociodemographic characteristics 48 dysfunctional voiding 48 biologic DMARD 48 glycated hemoglobin levels 48 ZOMIG Nasal Spray 48 Paromomycin IM Injection 48 glucose abnormalities 48 aldosterone antagonists 48 methodologically rigorous 48 affective psychosis 48 intestinal mucosal 48 suboptimal adherence 48 ICD implants 48 HRQOL 48 zoledronate 48 paricalcitol 48 HAM D# 48 adjuvant therapies 48 psychopathological symptoms 48 virological response 48 β blocker 48 peripheral insulin sensitivity 48 myocardial ischaemia 48 NATRECOR R 48 Comorbidity 48 postmarket surveillance 48 DACH platinum 48 APTIVUS r 48 torsade de pointes 48 ADCS ADL 48 psychotherapeutic interventions 48 CAARS 48 blinded randomized controlled 48 ICD therapy 48 Symbicort SMART 48 dopaminergic therapy 48 paroxetine sertraline 48 allele frequencies 48 titration phase 48 periprocedural 48 substance induced psychosis 48 serum folate concentrations 48 primary dysmenorrhoea 48 virologic suppression 48 inhaled AAT 48 chronic prostatitis chronic 48 discriminant validity 48 elevated IOP 48 RE LY ® 48 ACZ# 48 CVD mortality 48 hypersomnia 48 malabsorptive 48 COPD exacerbation 48 syndromal 48 DAPT 48 chromium supplementation 48 thyroid carcinoma 48 hepatic enzyme 48 golimumab CNTO 48 empiric therapy 48 unmeasured confounders 48 cystoid macular edema 48 RISPERDAL ® 48 COMT genotype 48 ISTODAX 48 PSVT 48 EBV infection 48 DSM IV diagnoses 48 biologic DMARDs 48 leukocyte count 48 montelukast 48 systemic corticosteroids 48 Bupropion 48 maximally tolerated 48 salivary flow 48 chronic periodontitis 48 antidiabetic drugs 48 Score DAS# 48 symptomatic hyponatremia 48 HbA 1c levels 48 A1c levels 48 HRQoL 48 symptomatic intracranial 48 antiarrhythmic 48 Nocturia 48 antithrombotic therapy 48 myocardial infarctions MIs 48 cortical activation 48 acromegalic patients 48 EMBEDA TM 48 sitaxsentan 48 glatiramer acetate 48 anastomotic leak 48 smoking cessation therapies 48 HF ACTION 48 postoperative complication 48 osteocalcin protein 48 HADS 48 extensive metabolizers 48 EQ 5D 48 circulating EPCs 48 postoperative AF 48 acute gout flares 48 observable characteristics 48 BEXXAR therapeutic regimen 48 oral methylnaltrexone 48 neurologic sequelae 48 venous thromboembolism prophylaxis 48 silent myocardial ischemia 48 apneic episodes 48 tumor histology 48 decrements 48 STRIDE PD 48 foveal thickness 48 haematological toxicity 48 MDQ 48 intravenous tPA 47 hepatic metastases 47 daytime alertness 47 psychotic disorders 47 cortical stimulation 47 topical NSAIDs 47 guanfacine extended release 47 AST ALT 47 plasma glucose concentration 47 ATACAND 47 tocilizumab 47 QVAR ® 47 electrical cardioversion 47 logistic regressions 47 dose Iluvien 47 authors hypothesized 47 posttransplant 47 major depressive disorder 47 reteplase 47 intact parathyroid hormone 47 therapeutic equivalence 47 EMSAM 47 Atomoxetine 47 baseline LDH 47 postoperative hemorrhage 47 antiangiogenic drugs 47 tumorigenicity 47 psychotherapies 47 Elitek 47 indolent lymphomas 47 NATRECOR ® 47 neovascularisation 47 dysfunction LVSD 47 Exacerbations 47 suicide attempters 47 varenicline Chantix 47 soluble CD# 47 endoscopic gastric ulcers 47 pyridostigmine 47 serum BDNF 47 Substance misuse 47 pharmacological approaches 47 dalteparin 47 eculizumab therapy 47 Oropharyngeal Candidiasis 47 hematopoietic cancers 47 QVAR R 47 LHRH agonist 47 LTRA 47 oral antidiabetes drugs 47 Paroxetine 47 interobserver 47 salivary cortisol 47 pathophysiological mechanisms 47 chronic airway inflammation 47 serum homocysteine 47 rheumatic disorders 47 AGGRASTAT R tirofiban hydrochloride 47 intraclass correlation coefficient 47 postoperative chemotherapy 47 lipid lowering medications 47 dopamine antagonism 47 Lubiprostone 47 DLQI 47 arterial thromboembolic events 47 parasitological 47 intestinal permeability 47 APTIVUS ritonavir 47 peak plasma concentrations 47 Vectibix monotherapy 47 exogenous insulin 47 MMSE score 47 nephrotoxicity 47 Testosterone deficiency 47 emotional dysregulation 47 tolterodine 47 epidural steroid injection 47 acute postoperative 47 sub maximal 47 O PPDS 47 AGILECT ® 47 intraclass correlation coefficients 47 oral naltrexone 47 PASI scores 47 dosage regimen 47 methotrexate therapy 47 vascularisation 47 IFN alfa 47 hyperprolactinemia 47 cardiac contractility 47 cilostazol 47 ziprasidone 47 nitrofurantoin 47 SCr 47 multivariable adjustment 47 baroreceptor 47 opioid substitution 47 curative therapy 47 antiepileptic medication 47 immune modulating 47 PRIALT 47 macrovascular events 47 mu opioid 47 Tasigna prolongs 47 nicardipine 47 univariate analyzes 47 vasoactive 47 UDCA 47 antibiotic regimens 47 pharmacologic therapies 47 dorzolamide 47 Major Depressive Disorder 47 AGILECT R 47 anabolic androgenic steroid 47 Visual Analogue Scale VAS 47 weekly subcutaneous injections 47 hematologic toxicity 47 Sycrest 47 external beam radiotherapy 47 imipramine 47 Glypromate 47 premenstrual symptoms 47 extrapyramidal symptoms 47 androgen depletion 47 phytoestrogen intake 47 unruptured aneurysm 47 nonpharmacologic 47 randomized controlled trials RCTs 47 coadministration 47 antihypertensive agents 47 biopsychosocial 47 EXJADE 47 FROVA 47 microscopic hematuria 47 airway responsiveness 47 erythropoietic 47 chronic renal insufficiency 47 vasodilators 47 teriflunomide 47 etiologic 47 pregabalin 47 vaginal estrogen 47 iNO 47 mGluR5 inhibitors 47 dual antiplatelet 47 serum bilirubin 47 morbidity mortality 47 PSA nadir 47 Removab 47 CYP #A# 47 airway hyperresponsiveness 47 antihyperglycemic 47 hypoperfusion 47 H2RAs 47 PCWP 47 ragweed allergic 47 ALVESCO HFA 47 piperacillin tazobactam 47 peginterferon 47 serum phosphate levels 47 GPRD 47 recurrent venous thromboembolism 47 postoperative morbidity 47 QTc intervals 47 airway narrowing 47 Cimzia TM 47 Dose escalation 47 neurocognition 47 antiarrhythmic drugs 47 CONCERTA ® 47 Crohn Disease Activity 47 RAS blockers 47 fludarabine cyclophosphamide 47 Longitudinal studies 47 neurologic dysfunction 47 genotypic resistance 47 RITUXAN ® 47 asymptomatic hyperuricemia 47 serum concentrations 47 psychiatric inpatients 47 rebleeding 47 adjunctively 47 psychosocial stressors 47 IQWiG 47 diabetic hypertensive 47 XR NTX 47 topical corticosteroids 47 interrater 47 EGFRIs 47 ARB telmisartan 47 EDSS score 47 citalopram hydrobromide 47 FENO 47 antiemetics 47 intrathecal baclofen 47 morphological abnormalities 47 miglustat 47 RLAI 47 antithrombotic 47 pharmacotherapy 47 clinically meaningful improvement 47 effector function 47 Escitalopram 47 serum magnesium 47 BEXXAR Therapeutic Regimen 47 EGFR mutation status 47 Lactobacillus KW 47 risk reducing salpingo 47 afterload 47 dysmenorrhoea 47 oral analgesics 47 HSCT 47 Hb levels 47 baroreflex 47 left ventricular diastolic 47 WOMAC pain 47 pouchitis 47 left ventricular systolic 47 repetitive transcranial magnetic stimulation 47 lipid lowering medication 47 TASKi3 47 beta blocker therapy 46 refractory CLL 46 cis retinoic acid 46 recurrent ischemia 46 Ocular Surface Disease 46 hypogonadal men 46 severe exacerbations 46 tipranavir r 46 XGEVA 46 antiresorptive 46 symptomatic VTE 46 Genetic variants 46 colorectal adenoma 46 CAM modalities 46 FACIT 46 urolithiasis 46 intratumoral 46 DAS# scores 46 histologic subtype 46 μmol L 46 STEP BD 46 schizophrenia schizoaffective disorder 46 receptor subtypes 46 intermittent dosing 46 quinolone 46 intra ocular pressure 46 neuropsychological impairment 46 hydroxyvitamin D levels 46 trials RCTs 46 MADRS score 46 intravenous diuretics 46 eosinophilia 46 intravenous bisphosphonates 46 cerebral oxygenation 46 lipid lowering therapy 46 Vasogen Celacade 46 SHPT 46 depot antipsychotics 46 achieving PASI 46 PhG alpha 1 46 cytochrome c oxidase 46 maturational 46 antibiotic prophylaxis 46 intravesical 46 antiviral regimens 46 rFVIIa 46 bivariate analyzes 46 echocardiographic parameters 46 ADAS Cog 46 psychiatric outpatients 46 visilizumab 46 tumor necrosis 46 cortical excitability 46 Neuropsychiatric Inventory 46 Genetic predisposition 46 TOPAMAX ® 46 PLMs 46 upper gastrointestinal GI 46 NeuroStar TMS Therapy 46 atrophic gastritis 46 parasitemia 46 conjugated equine estrogen 46 rTMS 46 cluster randomized controlled 46 nocturnal hypoglycaemia 46 ICD implantation 46 vidofludimus 46 antiepileptic drugs AEDs 46 refore 46 Degarelix 46 immunotoxicity 46 KRAS status 46 episodic migraine 46 elevated LDH 46 Raptiva r 46 platelet activation 46 macrolide antibiotics 46 ispinesib administered 46 semistructured interview 46 potent antiretroviral therapy 46 depression suicidal ideation 46 relapsed MM 46 SSRI prescriptions 46 malaria endemic regions 46 Pharmacologic 46 loop diuretics 46 opioid analgesia 46 Histalean TM 46 subsyndromal 46 cinacalcet 46 ejaculatory function 46 intracranial stenosis 46 physiologic mechanisms 46 lipid altering 46 PASI score 46 angiographic restenosis 46 abdominal adiposity 46 #mg dose [001] 46 Hepatotoxicity 46 plasma homocysteine 46 erythrocyte sedimentation rate 46 authors conclude 46 cardiac repolarization 46 hypocalcemia 46 urinary cadmium 46 methodologic 46 acting inhaled anticholinergic 46 Fibrillex TM 46 eprodisate Fibrillex TM 46 meta analytic review 46 Paliperidone 46 mg kg dose 46 tarenflurbil 46 % CI #.#-#.# [008] 46 idiopathic Parkinson disease 46 CIMZIA R 46 inhaled budesonide 46 aromatase inhibitor therapy 46 nonvertebral fractures 46 spirometric 46 nonalcoholic steatohepatitis NASH 46 somatization 46 UPDRS Part III 46 sustained virological response 46 EBRT 46 multiple linear regression 46 Erectile function 46 Severe Primary IGFD 46 manic hypomanic 46 serum HCV RNA 46 OHQ 46 inhaled bronchodilators 46 detrusor 46 parkinson disease 46 androgen deficiency 46 diabetes mellitus DM 46 insulin detemir 46 growth hormone secretion 46 statistically significant p = 46 platelet inhibitor 46 Reclast Aclasta 46 QALE 46 neutrophil counts 46 plasma leptin 46 NYHA functional class 46 insulin sensitizing drug 46 atypical neuroleptics 46 virological suppression 46 mesalamine granules 46 serotonin reuptake inhibition 46 cognitive behavioral psychotherapy 46 nadolol 46 isoflavone supplement 46 CAELYX 46 cytoreductive nephrectomy 46 Provent Therapy 46 YONDELIS 46 Lucentis ranibizumab Genentech 46 biologic therapy 46 postintervention 46 gastroduodenal 46 XZK 46 CMV reactivation 46 AGHD 46 somatostatin analog 46 Meta analyzes 46 ENGAGE AF TIMI 46 MIRP 46 testosterone supplementation 46 hyperactivity inattention 46 inter rater reliability 46 induced sputum 46 Main Outcome Measure 46 linear regression analyzes 46 serum estradiol 46 KETEK 46 N acetylcysteine 46 BPRS 46 postmarketing surveillance 46 predisposing factor 46 electroacupuncture 46 duloxetine Cymbalta 46 Zemplar Capsules 46 resynchronization therapy 46 CK # plasma concentrations 46 schizophrenia CIAS 46 psychostimulants 46 gastric cardia 46 mentally disordered offenders 46 intravenous dosing 46 comorbid diagnoses 46 inpatient hospitalizations 46 mu receptors 46 immunosuppression therapy 46 PREVENT IV 46 #HT#A receptor 46 #mg doses [002] 46 prospective multicentre 46 logistic regression model 46 extracolonic findings 46 immuno suppression 46 intravesical chemotherapy 46 LATUDA 46 MMRs 46 morbidity 46 haematological 46 MCID 46 medullary thyroid carcinoma 46 cytopenia 46 Liver transplantation 46 sleep apneas 46 percutaneous vertebroplasty 46 antirheumatic 46 lipid elevations 46 FOLFIRINOX 46 posaconazole 46 femoral shaft fracture 46 chemoprevention trials 46 serum IgE 46 aromatase inhibitors AIs 46 ONTAK 46 cerebral microbleeds 46 microsimulation model 46 noncognitive 46 rimonabant #mg 46 generalized anxiety disorder 46 ACOMPLIA R 46 Oral corticosteroids 46 SSc 46 prolactin levels 46 prostate carcinogenesis 46 Randomized controlled 46 Angiox R 46 CPT code 46 fluoxetine Prozac 46 overt nephropathy 46 Rotigotine 46 systolic dysfunction 46 hypomanic episodes 46 GRANISOL 46 isoproterenol 46 Lu AA# 46 Lamotrigine 46 NICE guideline 46 somatoform disorder 46 status epilepticus 46 HER2 overexpression 46 Socioeconomic status 46 HYVET 45 Observational studies 45 oral corticosteroids 45 impaired cognition 45 P ≤ 45 antidiabetic therapy